Research Highlight Published: 01 June 2006 Sevelamer for treating hyperphosphatemia in pediatric CKD patients Rachael Williams Nature Clinical Practice Nephrology 2, 296 (2006) Cite this article ...

Hyperphosphatemia is a serious medical condition that occurs in nearly all patients with End Stage Renal Disease (ESRD). Annually there are over 450,000 individuals in the U.S. that require medication ...

The global hyperphosphatemia treatment market grew from $3.57 billion in 2022 to $3.98 billion in 2023 at a compound annual growth rate (CAGR) of 11.3%. The Russia-Ukraine war disrupted the ...

In this video, Kevin Martin, MD, discusses treatment options available to patients with hyperphosphatemia.

In the U.S., Ardelyx is pursuing approval of tenapanor for the treatment of hyperphosphatemia in adult patients with CKD on dialysis who have had an inadequate response or intolerance to phosphate ...

The goal of hyperphosphatemia treatment should be to reduce serum phosphorus to ?5.5mg/dL (or closer to normal levels) and alleviate negative clinical outcomes for patients with CKD, including ...

Increasing product launches and approval of novel drugs in key regions around the globe are expected to fuel the global hyperphosphatemia drugs market growth in the near future. For instance, in 2016, ...

In this video, Kevin Martin, MD, discusses new and emerging technologies in the field of hyperphosphatemia.

Key Takeaways from the Market Study The global hyperphosphatemia market is expected to reach US$ 20.24 billion by 2033, growing at a CAGR of 4.8%. Iron-based phosphate binder is expected to grab 20% ...

Among the 184 survivors of 24-hour CRRT, hyperphosphatemia was associated with a significant 2.2 times and 2.6 times increased risk of death at 28 days and 90 days, respectively.

Major players in the hyperphosphatemia treatment market are Sanofi, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc, Akebia Therapeutics, Inc, Vifor Pharma Management Ltd. , Lupin Limited, ...